MBIO - Mustang Bio in-licenses vector-enhancing technology for gene therapy

Mustang Bio (MBIO) inks an agreement with SIRION Biotech GmbH securing rights to the latter's LentiBOOST technology for the development of MB-207, a gene therapy for X-linked severe combined immunodeficiency, also known as "bubble boy disease."The company says LentiBOOST enables a robust and reproducible process and reduces manufacturing costs by lowering the amount of lentiviral vectors needed for the production of the cell product.Under the terms of the deal, MBIO will pay SIRION an undisclosed upfront fee, milestones and royalties on net sales.Shares up 1% premarket on light volume.

For further details see:

Mustang Bio in-licenses vector-enhancing technology for gene therapy